Delayed Use of the Recombinant Human IL-1 Receptor Antagonist Anakinra in Five COVID-19 Patients with Pulmonary Fibrosis and Persistent Hypoxaemia: A Preliminary Report

Coronavirus disease 2019 (COVID-19) is currently a major public health problem. The development of pulmonary fibrosis secondary to acute respiratory distress syndrome (ARDS) is one of the expected sequelae. In this case series, we describe five instances of the use of anakinra in late-phase COVID-19...

Full description

Saved in:
Bibliographic Details
Main Authors: Daniel Nan, Cristina Abraira-Meriel, Sandra de la Roz-Fernandez, Tamara Maestre-Orozco, Jose Luis Hernandez, Marta Fernandez-Ayala
Format: article
Language:EN
Published: SMC MEDIA SRL 2021
Subjects:
R
Online Access:https://doaj.org/article/2c88b730844e40fd9fd30026631acb45
Tags: Add Tag
No Tags, Be the first to tag this record!